Equities Analysts Issue Forecasts for RDY Q4 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Research analysts at Zacks Research increased their Q4 2026 earnings per share estimates for Dr. Reddy’s Laboratories in a report issued on Monday, March 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.20 for the quarter, up from their previous forecast of $0.19. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%.

Other equities analysts have also issued research reports about the company. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Dr. Reddy’s Laboratories Trading Up 0.9 %

NYSE:RDY opened at $13.47 on Thursday. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a 1-year low of $12.50 and a 1-year high of $16.89. The firm has a market capitalization of $11.24 billion, a price-to-earnings ratio of 21.44 and a beta of 0.48. The stock has a fifty day simple moving average of $13.74 and a 200 day simple moving average of $14.73.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

A number of institutional investors have recently bought and sold shares of the business. Robeco Institutional Asset Management B.V. boosted its position in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after acquiring an additional 9,373,412 shares during the period. Royal Bank of Canada boosted its position in Dr. Reddy’s Laboratories by 403.1% during the 4th quarter. Royal Bank of Canada now owns 10,037,246 shares of the company’s stock worth $158,489,000 after acquiring an additional 8,042,163 shares during the period. Renaissance Technologies LLC boosted its position in Dr. Reddy’s Laboratories by 382.9% during the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company’s stock worth $148,717,000 after acquiring an additional 7,467,979 shares during the period. Aikya Investment Management Ltd boosted its position in Dr. Reddy’s Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock worth $88,590,000 after acquiring an additional 4,523,303 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Dr. Reddy’s Laboratories by 405.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company’s stock worth $84,643,000 after acquiring an additional 4,301,212 shares during the period. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.